Further Amendment to Duties Addressing the Synthetic Opioid Supply Chain in the People's Republic of China as Applied to Low-Value Imports

Executive Order Number

14256

President

Donald Trump

Signed

April 2, 2025

Published

April 7, 2025

Source

Federal Register

Original Document

https://www.govinfo.gov/content/pkg/FR-2025-04-07/pdf/2025-06027.pdf

AI-Generated Summary

Executive Order Summary

Purpose

The purpose of this executive order is to address the issue of deceptive shipping practices by shippers based in the People's Republic of China (PRC) and Hong Kong, which are used to smuggle illicit substances, particularly synthetic opioids, into the United States. The order aims to curb this by eliminating the duty-free de minimis treatment for certain low-value shipments from the PRC and Hong Kong.

Key Actions or Directives

• Elimination of De Minimis Exemption: As of 12:01 am eastern daylight time on May 2, 2025, duty-free de minimis treatment under 19 U.S.C. 1321(a)(2)(C) will no longer be available for products from the PRC and Hong Kong that are described in section 2(a) of Executive Order 14195, as amended.
• Assessment of Duties: Shipments valued at or under $800 that would otherwise qualify for the de minimis exemption will be subject to duties. These shipments must be entered through the Automated Commercial Environment (ACE) operated by U.S. Customs and Border Protection (CBP).
• Duty Rates for Postal Items: Postal items from the PRC and Hong Kong will be subject to either an ad valorem duty of 30% of the item's value or a specific duty of $25 per item until June 1, 2025, and $50 per item thereafter.
• Bond Requirement: Carriers transporting international postal items from the PRC and Hong Kong must have an international carrier bond to ensure duty payment.
• Implementation and Monitoring: The Secretary of Homeland Security is tasked with implementing the order, and the Secretary of Commerce must submit a report within 90 days on the order's impact and potential further actions.

Significant Changes to Policy or Law

• Suspension of De Minimis Exemption: The order suspends the duty-free de minimis treatment for specified goods from the PRC and Hong Kong, which is a significant change to existing trade policy.
• New Duty Impositions: The introduction of new duty rates for low-value shipments from the PRC and Hong Kong represents a change in how these goods are taxed upon entry into the United States.

Potential Impacts

• Government Agencies: The Department of Homeland Security, particularly CBP, will face increased workload and may need to adjust regulations and procedures to implement the order effectively.
• Citizens: U.S. consumers may experience higher costs for goods imported from the PRC and Hong Kong due to the new duties, potentially affecting the affordability of certain products.
• International Relations: The order may strain relations with the PRC and Hong Kong, as it targets their shipping practices and could be perceived as a trade barrier.

Main Stakeholders Affected

• U.S. Customs and Border Protection (CBP): Responsible for implementing the new duties and ensuring compliance.
• Department of Homeland Security: Tasked with overall implementation of the order.
• U.S. Consumers: May face increased costs for goods from the PRC and Hong Kong.
• Shippers and Carriers from the PRC and Hong Kong: Will need to comply with new duty requirements and may face increased operational costs.
• U.S. Industries: May be affected by changes in supply chains and costs of goods.

Notable Legal, Constitutional, or Political Implications

• Legal Authority: The order is issued under the authority of the International Emergency Economic Powers Act (IEEPA), the National Emergencies Act, and other relevant statutes, indicating a legal basis for the President's actions.
• Constitutional Considerations: The order does not appear to raise significant constitutional issues, as it falls within the President's authority over foreign commerce and national emergencies.
• Political Implications: The order may be seen as part of a broader strategy to address the opioid crisis and could be politically contentious, especially in relation to U.S.-China trade relations. It may also face scrutiny from Congress and trade partners regarding its impact on international trade and compliance with trade agreements.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.